Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke

Inclusion Criteria: * Age 18-80 years old, gender is not limited; * Clinically confirmed acute ischemic stroke; * Within 6 hours of the onset of this stroke; * NIHSS score of 4-24 at enrollment; * mRS score before onset≤ 1 point; * Subject and subject's agent are able and willing to sign informed consent. Exclusion Criteria: * CT indicates intracranial hemorrhagic diseases, such as hemorrhagic stroke, subdural hematoma, ventricular hemorrhage, or subarachnoid hemorrhage, etc.; * Previously known severe liver or kidney insufficiency (ALT or AST is greater than 3.0×ULN; serum Creatinine (SCr) is greater than 1.5×ULN, Creatinine Clearance (CrCl) is less than 50 ml/min or dialysis; * Systolic blood pressure≥220 mmHg or \<90mmHg； * Recent stroke within prior 1 month； * Hypersensitive to edaravone, (+)-2- dexborneol or auxiliary materials; * Prior receipt of edaravone or any other neuroprotective drugs; * History of congenital or acquired hemorrhagic disease, coagulation factor deficiency disease, or thrombocytopenic disease, etc.; * Pregnancy, lactation, or planned pregnancy within 90 days; * Those who cannot complete informed consent or follow-up treatment due to severe mental disorder or dementia; * Those with a malignant tumor, severe systemic diseases, or predict survival time \<90 days; * Participate in another interventional clinical study within 30 days before randomization or participate in another interventional clinical study; * The investigators consider the patients are not suitable for this trial.